Mach 1 Financial Group LLC Increases Holdings in Medtronic PLC $MDT

Mach 1 Financial Group LLC grew its stake in Medtronic PLC (NYSE:MDT) by 351.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,402 shares of the medical technology company’s stock after acquiring an additional 8,878 shares during the quarter. Mach 1 Financial Group LLC’s holdings in Medtronic were worth $1,095,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Lodestone Wealth Management LLC purchased a new stake in shares of Medtronic in the fourth quarter worth $27,000. Anfield Capital Management LLC grew its stake in shares of Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Medtronic in the fourth quarter worth $29,000. GoalVest Advisory LLC purchased a new stake in shares of Medtronic in the fourth quarter worth $29,000. Finally, Valley Wealth Managers Inc. purchased a new stake in shares of Medtronic in the third quarter worth $29,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic said the SPR Therapeutics deal will strengthen its neuromodulation portfolio and broaden treatment options for chronic pain patients, which could support longer-term growth in a key business area. Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
• Positive Sentiment: The acquisition adds temporary peripheral nerve stimulation technology, which could help Medtronic deepen its presence in pain management and neuromodulation markets. Medtronic plans to buy SPR Therapeutics for $650 million to expand pain treatment options
• Neutral Sentiment: Piper Sandler kept a Hold rating on Medtronic, suggesting analysts are not yet calling for a major re-rating after the deal announcement. Piper Sandler Sticks to Their Hold Rating for Medtronic (MDT)
• Neutral Sentiment: Healthcare stocks were broadly mixed, so Medtronic’s move may also reflect sector-level rotation rather than company-specific weakness alone. Sector Update: Healthcare Stocks Mixed Late Afternoon
• Negative Sentiment: Some market commentary described Medtronic’s stock as sliding after the acquisition announcement, indicating investors may be cautious about the deal price and its impact on near-term returns. Medtronic (MDT) Stock Slides as Company Announces $650M SPR Therapeutics Deal

Medtronic Stock Down 0.6%

NYSE MDT opened at $78.09 on Thursday. The stock’s 50-day moving average price is $83.94 and its 200-day moving average price is $93.34. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 52 week low of $74.40 and a 52 week high of $106.33. The company has a market capitalization of $100.26 billion, a P/E ratio of 21.75, a price-to-earnings-growth ratio of 1.87 and a beta of 0.62.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter last year, the company earned $1.38 earnings per share. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. On average, equities research analysts predict that Medtronic PLC will post 5.56 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were paid a $0.71 dividend. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.6%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Wall Street Analyst Weigh In

MDT has been the topic of a number of recent research reports. Weiss Ratings cut Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, April 21st. Needham & Company LLC reissued a “buy” rating and issued a $120.00 target price on shares of Medtronic in a research note on Thursday, March 26th. Jefferies Financial Group reissued a “hold” rating and issued a $95.00 target price on shares of Medtronic in a research note on Thursday, April 23rd. Argus cut their target price on Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Finally, Barclays increased their target price on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Fifteen analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $107.80.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).